Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 621
Toronto, Ontario, Canada
- Arcutis Clinical Site 630
Santo Domingo, Dominican Republic
- Arcutis Clinical Site 603
Mountain Brook, Alabama, United States
- Arcutis Clinical Site 604
Scottsdale, Arizona, United States
- Arcutis Clinical Site 609
Fountain Valley, California, United States
- Arcutis Clinical Site 608
Los Angeles, California, United States
- Arcutis Clinical Site 618
Los Angeles, California, United States
- Arcutis Clinical Site 611
Rancho Santa Margarita, California, United States
- Arcutis Clinical Site 610
Boca Raton, Florida, United States
- Arcutis Clinical Site 602
Coral Gables, Florida, United States
- Arcutis Clinical Site 613
Delray Beach, Florida, United States
- Arcutis Clinical Site 607
Miami, Florida, United States
- Arcutis Clinical Study Site 628
Miami, Florida, United States
- Arcutis Clinical Site 627
West Lafayette, Indiana, United States
- Arcutis Clinical Site 606
Arlington, Texas, United States
- Arcutis Clinical Site 619
Frisco, Texas, United States
- Arcutis Clinical Study Site 619
Frisco, Texas, United States
- Arcutis Clinical Site 605
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Mar 2021
- Primary completion
- 11 May 2022
- Completion
- 11 May 2022
- Last update posted
- 10 Mar 2023
- Registered enrollment
- 10
- Registry id
- NCT04746911
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.